Repression of interferon regulatory factor-4(IRF4)hyperactivation restricts murine lupus  

作　　者：Shijun He Huihua Ding Li Chen Yiwei Shen Yuting Liu Fenghua Zhu Xiaoqian Yang Nan Shen Zemin Lin Jianping Zuo 

机构地区：[1]Innovation Research Institute of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai,China [2]Laboratory of Immunopharmacology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China [3]Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第6期2475-2477,共3页信号转导与靶向治疗（英文）

基　　金：the National Natural Science Foundation of China(Grant Number:81903882,81871240,82001709);the Science and Technology Commission of Shanghai Municipality(Grant Number:22ZR1473700,21S11907700);"Science and Technology Innovation Action Plan"medicine innovation fund by Science and Technology Commission of Shanghai Municipality(Grant Number:21Y31900200).

摘　　要：Dear Editor,Hyperactivation of the type I interferon(IFN)signature has been observed in several systemic autoimmune conditions,and the type I IFN receptor antagonist Saphnelo(anifrolumab-fnia)has been approved in 2021 by the Food and Drug Administration(FDA)in the US.The launch of Saphnelo marked the only new treatment approved for systemic lupus erythematosus(SLE)in more than 10 years.

关 键 词：LUPUS INTERFERON ACTIVATION 

分 类 号：R593.24[医药卫生—内科学]